

Causal association between sleep traits and diabetic nephropathy

Chen Ji, Chunyang Zhang*

General Practice, Changshou Street Community Health Service Hospital, Shanghai, China

Submitted: 8 February 2025; Accepted: 23 July 2025

Online publication: 20 September 2025

Arch Med Sci 2025; 21 (6): 2493–2501

DOI: <https://doi.org/10.5114/aoms/208530>

Copyright © 2025 Termedia & Banach

*Corresponding author:

Chunyang Zhang

General Practice

Community Health

Service Hospital

Changshou Street

Shanghai, China

E-mail: 13611887990@139.com

Abstract

Introduction: The study aimed to explore the causal association between genetically predicted sleep traits (chronotype, sleep duration, short sleep duration, long sleep duration, insomnia, daytime sleepiness, and sleep apnea syndrome) and diabetic nephropathy (DN).

Material and methods: A two-sample Mendelian randomization (MR) design was used to analyze summary data from genome-wide association studies of sleep traits and DN. The main analysis was conducted using the inverse variance weighted (IVW) method, and robustness was tested using the weighted median, weighted mode, and MR-Egger regression methods. Heterogeneity was detected using Cochran's Q-test, horizontal pleiotropy using the MR-Egger regression method, potential outliers using MR-PRESSO, and single-nucleotide polymorphisms driving the results using a leave-one-out analysis.

Results: The genetic prediction results indicated no statistically significant associations between the sleep traits and DN (all IVW $p > 0.05$). However, the weighted median analysis showed a possible causal association between long sleep and DN (OR < 0.01, 95% CI: 0–0.70, $p = 0.04$) and a borderline possible causal association between sleep apnea syndrome and DN (OR = 2.50, 95% CI: 0.99–6.35, $p = 0.05$). Cochran's Q-test indicated possible heterogeneity for the sleep duration analysis ($p = 0.01$), but no horizontal pleiotropy or outliers were detected (all $p > 0.05$).

Conclusions: This MR analysis suggested no causal associations between the sleep traits (chronotype, sleep duration, short sleep duration, long sleep duration, insomnia, daytime sleepiness, and sleep apnea syndrome) and DN. Further in-depth research is needed to examine the relationship between sleep and DN.

Key words: sleep, diabetic nephropathy, Mendelian randomization, causality.

Introduction

Diabetic nephropathy (DN) is a microvascular complication of diabetes mellitus. DN may progress to chronic kidney disease (CKD) and is a major cause of end-stage kidney disease [1]. Diabetic kidney disease is a distinct clinical-pathologic entity clinically presenting as microalbuminuria or macroalbuminuria, increased arterial blood pressure, and a distinct morphologic pattern of injury on renal biopsy [1]. Approximately 20–40% of patients with diabetes develop diabetic kidney disease [2]. The risk factors for diabetic kidney disease include genetic factors, smok-



ing, duration of diabetes, early onset of diabetes, poor glycemic control, obesity, hypertension, proteinuria, dyslipidemia, and older age [1].

Sleep is a complex, active state of unconsciousness produced by the body, during which the brain is in a relative state of rest and is reactive primarily to internal stimuli. The exact purpose of sleep has not been fully elucidated, but theories attempting to identify why we sleep have been proposed: the inactivity theory, the energy conservation theory, the restoration theory, and the brain plasticity theory [3]. The impact of DN on sleep quality is fairly well documented [4]; however, whether sleep can influence the occurrence of DN remains poorly understood, although accumulating evidence suggests that obstructive sleep apnea (OSA) could be a risk factor for DN or be associated with DN [5]. Indeed, a parallel increase in the prevalence of OSA, type 2 diabetes mellitus, and DN has been observed in India and China [6]. Short or long sleep duration [7] and OSA [6] have been associated with DN, but whether genetically predicted sleep parameters are associated with a genetic predisposition to DN remains to be determined. Furthermore, treating OSA with continuous positive airway pressure does not improve DN parameters [8].

Data on millions of single-nucleotide polymorphisms (SNPs) and their related phenotypes have been provided in recent decades by genome-wide association studies (GWASs), revolutionizing the field of genetics and medicine, especially for com-

plex traits and diseases [9]. The Mendelian randomization (MR) methodology uses common genetic variants as instrumental variables for various environmental exposures. It allows the exploration of possible causal associations between these exposures and outcomes. Two-sample MR uses the associations between SNPs and exposure and between SNPs and outcomes from different GWASs to combine them into a single analysis to estimate causality. Under key assumptions, MR reduces the impact of reverse causation and confounding that often substantially impede or mislead the interpretation of epidemiological studies [9].

Therefore, this study aimed to explore the causal association between genetically predicted sleep traits and DN using the MR methodology.

Material and methods

Study design

The overall design of this two-sample MR study is illustrated in Figure 1. First, we identified and curated large-scale, publicly available GWAS summary statistics for seven distinct sleep traits (exposures) and DN (outcome). Second, for each sleep trait, we selected independent single nucleotide polymorphisms (SNPs) that were strongly associated with the exposure ($p < 5 \times 10^{-8}$) and were not in linkage disequilibrium ($r^2 < 0.001$ within a 10 Mb window) to serve as instrumental variables (IVs). Third, we performed the primary causal estimation using the inverse-variance weighted (IVW) method. Finally, to ensure the robustness of our findings, we conducted a comprehensive suite of sensitivity analyses, including the weighted median, weighted mode, MR-Egger regression, MR-PRESSO, and leave-one-out analyses, to detect and account for potential horizontal pleiotropy and heterogeneity.

This study was conducted using exclusively publicly available summary-level data. The original GWASs were approved by ethical committees and were performed according to the tenets of the Declaration of Helsinki. Hence, no additional ethical approval was necessary. The validity of our MR study hinges on three key assumptions: 1) the relevance assumption, which posits that the selected IVs are robustly associated with their corresponding sleep trait; 2) the independence assumption, which requires that there are no unmeasured confounders of the association between the IVs and DN; and 3) the exclusion-restriction assumption (or no horizontal pleiotropy), which states that the IVs affect DN only through their effect on the sleep trait and not via any independent biological pathways [9].

Data source

The GWAS data for DN were from the FinnGen project (<https://www.finngen.fi/en>). The dataset




Figure 1. Schematic representation of the Mendelian randomization analysis

contains data on 3283 patients with DN and 181,704 controls (16,380,336 SNPs), all from Finland.

The chronotype dataset was from a published study [10]. It contains data on 403,195 individuals from the United Kingdom (UK). The sleep duration data were from 446,118 individuals from the UK [11]. That dataset contains information about long sleep duration (339,926 individuals) and short sleep duration (446,118 individuals) [11]. The data about sleep apnea syndrome were from 25,008 cases and 337,630 controls from Canada, the United States of America (USA), Finland, the UK, and Australia [12]. The datasets on insomnia (from Europe) [13] and daytime sleepiness (from the USA) [11] were from published studies (Supplementary Table SI).

Instrumental variable selection

The IVs included in this study had to meet the following criteria. First, the SNPs significantly associated with the sleep traits were screened, with a threshold of $p < 5 \times 10^{-8}$ [14]. Then, the SNPs with a minimum minor allele frequency (MAF) of > 0.01 were selected. Finally, SNPs showing linkage disequilibrium (LD) were filtered out based on $R^2 < 0.001$ and a window size of 10,000 kb. In cases where a selected IV for an exposure was not present in the outcome summary data, SNPs with high LD ($R^2 > 0.8$) were sought as proxy SNPs for replacement. The F-statistic was calculated for each SNP in the IV to assess IV strength and identify potential weak instrument bias between IVs and exposure factors. The formula was $F = R^2 \times (N - 2) / (1 - R^2)$. An F-statistic > 10 was required to mitigate weak instrument bias [15].

Mendelian randomization analysis

The primary method for MR analysis to assess the causal association between exposure and outcome risks in this study was the inverse variance weighted (IVW) method [16]. The results were provided as odds ratios (ORs) and 95% confidence intervals (CIs). If the IVW results were statistically significant, their robustness was tested using complementary MR methods, including the MR-Egger [17], weighted median [18], and weighted mode [19]. All analyses were carried out using the “TwoSampleMR” package in R 4.0.5 (The R Project for Statistical Computing, www.r-project.org). The analyses were visualized using scatter and forest plots.

Sensitivity analysis

Heterogeneity was detected using Cochran's Q test; $p > 0.05$ indicated low heterogeneity, suggesting that the estimates among IVs were randomly distributed and had little impact on the IVW analysis [20]. Funnel plots were generated to

visualize heterogeneity. Horizontal pleiotropy was detected using the MR-Egger regression method; an intercept near 0 or $p > 0.05$ indicated the absence of pleiotropy [20]. The MR pleiotropy residual sum and outlier (MR-PRESSO) analysis was used to detect potential outliers, indicated by $p < 0.05$, and re-estimate the causal associations after outlier removal [20]. A leave-one-out analysis was used to determine whether single SNPs drove the results; the leave-one-out analysis was shown as forest plots.

Results

Instrument variable selection

In this study, when performing MR analyses with chronotype, sleep duration, short sleep duration, long sleep duration, insomnia, daytime sleepiness, and sleep apnea syndrome as exposures, 122, 70, 26, 10, 13, 33, and 5 IVs were identified, respectively. The mean F-statistics for these IVs were 45.67, 40.67, 34.35, 31.91, 41.19, 42.45, and 43.43, respectively. The minimum F-statistics ranged from 29.02 to 29.88 for the different exposures, while the maximum values ranged from 52.98 to 168.52. No SNPs were unmatched in the summary data for chronotype, short sleep duration, insomnia, daytime sleepiness, and sleep apnea syndrome-related IVs. In contrast, two SNPs were unmatched for long sleep duration, without proxy SNPs being identified. The R^2 values, indicating the proportion of variance explained by the IVs for each trait, were 0.01, 0.006, 0.002, 0.001, 0.004, 0.003, and < 0.001 , respectively, for the different exposures. The selection of the IVs is summarized in Supplementary Table SII. All F-values were > 10 , indicating the absence of weak instrumental bias (Supplementary Table SIII).

Mendelian analysis results


Genetic prediction results indicated no statistically significant associations between the sleep traits and DN (all IVW $p > 0.05$) (Table I, Figures 2 and 3). The weighted median analysis showed a possible causal association between long sleep and DN (OR = 0, 95% CI: 0–0.70, $p = 0.04$) and a borderline possible causal association between sleep apnea syndrome and DN (OR = 2.50, 95% CI: 0.99–6.35, $p = 0.05$). However, these results must be interpreted cautiously, since the main MR analysis is IVW.

Sensitivity analysis

Heterogeneity among IVs can bias the results. Cochran's Q-test indicated possible heterogeneity for the sleep duration analysis ($p = 0.01$) (Supplementary Table SIV and Supplementary Figure S1).

Table I. Genetic prediction of the association between sleep characteristics and the risk of developing causal associations with diabetic nephropathy

Exposure	Outcome	N.SNPs	Methods	OR (95% CI)	P-value
Chronotype	Diabetic nephropathy	118	IVW	1.82 (0.91–3.65)	0.09
			MR-Egger	1.99 (0.22–17.87)	0.54
			Weighted median	1.68 (0.63–4.47)	0.3
			Weighted mode	1.24 (0.09–16.83)	0.87
Sleep duration		67	IVW	0.82 (0.48–1.39)	0.45
			MR-Egger	0.53 (0.07–4.26)	0.55
			Weighted median	0.57 (0.29–1.11)	0.1
			Weighted mode	0.48 (0.15–1.54)	0.22
Short sleep duration		24	IVW	1.19 (0.17–8.42)	0.86
			MR-Egger	21959.04 (0.66–728072219.24)	0.07
			Weighted median	3.58 (0.27–47.70)	0.33
			Weighted mode	15.81 (0.23–1074.40)	0.21
Long sleep duration		8	IVW	0.05 (0–30.86)	0.37
			MR-Egger	37572.36 (0–6154502976708.14)	0.32
			Weighted median	0 (0–0.70)	0.04
			Weighted mode	0 (0–5.39)	0.15
Insomnia		13	IVW	1.20 (0.76–1.89)	0.44
			MR-Egger	1.07 (0.29–3.96)	0.92
			Weighted median	1.31 (0.73–2.35)	0.36
			Weighted mode	1.39 (0.63–3.03)	0.43
Daytime sleepiness		32	IVW	0.45 (0.11–1.93)	0.28
			MR-Egger	3.26 (0–3151.51)	0.74
			Weighted median	0.91 (0.12–6.8)	0.92
			Weighted mode	1.12 (0.04–31.86)	0.95
Sleep apnea syndrome		5	IVW	1.86 (0.70–4.92)	0.21
			MR-Egger	9.57 (0.05–2009.71)	0.47
			Weighted median	2.50 (0.99–6.35)	0.05
			Weighted mode	3.30 (0.99–11.03)	0.12

**Figure 2.** Mendelian randomization analysis of the causal association between sleep traits and diabetic nephropathy. Scatter plots for chronotype (A), sleep duration (B)




Figure 2. Cont. Short sleep duration (C), long sleep duration (D), insomnia (E), daytime sleepiness (F), and sleep apnea syndrome (G)

The third key assumption for the validity of MR analyses is the absence of horizontal pleiotropy. MR-Egger regression suggested the absence of horizontal pleiotropy ($\text{all } p > 0.05$) (Supplementary Table SIV). MR-PRESSO did not detect outliers (Supplementary Table SV), suggesting the robustness of the results. The leave-one-out analysis suggested that no single SNP drove the results (Supplementary Figure S2), also suggesting robustness.

Discussion

This two-sample MR study explored the causal association of sleep traits, including chronotype,

sleep duration, short sleep duration, long sleep duration, short sleep duration, long sleep duration, insomnia, daytime sleepiness, and sleep apnea syndrome, with DN. The results suggested no causal associations between sleep traits and DN based on the primary IVW analyses. Still, the weighted median analysis showed a possible causal association between long sleep and DN and a borderline possible causal association between sleep apnea syndrome and DN.

DN affects the sleep quality of the patients, but the relationship is complex and is influenced by physical and psychological factors [4]. The present MR study did not explore that association. On the other hand, whether sleep can influence the occurrence of DN remains poorly understood. Never-




Figure 3. Mendelian randomization analysis of the causal association between sleep traits and diabetic nephropathy. Forest plots for chronotype (A), sleep duration (B), short sleep duration (C), long sleep duration (D)




Figure 3. Cont. Insomnia (E), daytime sleepiness (F), and sleep apnea syndrome (G)

theless, poor sleep quality is associated with poor health outcomes. Indeed, short and long sleep durations are associated with overall mortality (absolute increases in mortality of 12% and 39%, respectively) and cognitive decline [21]. Compared with 7 h of sleep, a 1-h decrease in sleep duration was associated with an 11% increase in the risk of cardiovascular heart disease, while a 1-h increase in duration was associated with a 7% increase [22]. In addition, compared with 7 h of sleep, a 1-h decrease in sleep duration was associated with a 9% increase in the risk of type 2 diabetes mellitus, while a 1-h increase in duration was associated with a 14% increase [23]. Short sleep was also associated with falls, accidents, and injuries, incident obesity, and incident hypertension [21]. Although those previous studies did not examine

DN, diabetes is a prerequisite for DN diagnosis, and obesity and hypertension are risk factors for DN [1]. The intermittent hypoxia observed in sleep apnea is also associated with a systemic proinflammatory state [24] that can contribute to the occurrence of DN. Sleep disturbances are also associated with systemic inflammation [25]. Indeed, inflammation is involved in the pathogenesis of DN [26]. Furthermore, OSA can influence the blood glucose levels [27].

Still, the present study showed no causal associations between sleep traits and DN, based on the IVW results. The weighted median analysis suggested the possibility of causal associations between long sleep duration and DN and between sleep apnea and DN, but those results were not observed in the IVW analysis. They must be interpret-

ed with caution, but suggest the possibility of an association that might warrant additional study. The pathogenesis of many diseases is influenced by a combination of genetic and environmental factors [28]. Even though genetic factors are a major determinant of disease risk, environmental factors also play an important role [28]. Therefore, in the case of negative genetic results, as is the case here, examining whether there is an interaction between environmental factors and the exposures and outcomes, and how these factors affect the results, is necessary. Unfortunately, GWAS datasets do not contain such information. Longitudinal studies would be necessary to look into those points. Therefore, negative MR results do not mean that there is no association between the exposures and the outcomes, but that the genetically predicted risk of the exposure is not associated with the genetically predicted risk of the outcome. The absence of association may be because the genetic variation is insufficient to model the effect of exposure on outcome adequately. It is a known limitation of MR studies, especially where genetic variants have small or weaker effects on exposure.

This study had several strengths. It used a two-sample MR design and GWAS data from tens of thousands of individuals to evaluate the causal association between sleep traits, OSA, and DN. On the other hand, the study also had limitations. First, the GWAS data in the present study were from European, North American, and Australian populations (i.e., mainly of European ancestry), and their generalizability to other populations remains unknown. Second, some participants could have been included in both the exposure and the outcome, but it is impossible to determine the exact extent of the phenomenon. Still, using stringent statistics should minimize the impact of eventual overlap [29]. The selection of IVs can influence causal associations, and while the present study applied robust selection criteria, the inherent genetic architecture of the traits might limit the strength or number of available IVs. Third, MR studies assess the effect of lifelong genetic predisposition to an exposure, which may not fully capture the impact of acquired or fluctuating sleep patterns on DN risk. Finally, negative MR results indicate that the genetically predicted risk of the exposures is not associated with the genetically predicted risk of the outcome, which can occur if the genetic variation is insufficient to model the effect of exposure on outcome adequately, a known limitation where genetic variants have weaker effects on exposure.

In conclusion, the present MR analysis suggested no causal associations between sleep traits (chronotype, sleep duration, short sleep duration, long sleep duration, insomnia, daytime sleepiness, and sleep apnea syndrome) and DN. Further in-

depth research is needed to examine the relationship between sleep and DN.

Funding

No external funding.

Ethical approval

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

References

1. Rao LV/Rao LBV, Tan SH, Candasamy M, Bhattacharya SK. Diabetic nephropathy: an update on pathogenesis and drug development. *Diabetes Metab Syndr* 2019; 13: 754-62.
2. American Diabetes Association Professional Practice C. Introduction and Methodology: Standards of Care in Diabetes-2024. *Diabetes Care* 2024; 47 Suppl 1: S1-4.
3. Brinkman JE, Reddy V, Sharma S. Physiology of Sleep. StatPearls. Treasure Island (FL) ineligible companies. 2024.
4. Lien ASY, Jiang YD, Tsai JL, Hwang JS, Lin WC. Prediction of diabetic nephropathy from the relationship between fatigue, sleep and quality of life. *Appl Sci* 2020; 10: 3282.
5. Zamarron E, Jaureguizar A, Garcia-Sanchez A, et al. Obstructive sleep apnea is associated with impaired renal function in patients with diabetic kidney disease. *Sci Rep* 2021; 11: 5675.
6. Misra A, Shrivastava U. Obstructive sleep apnea and diabetic nephropathy. *Diabetes Technol Ther* 2016; 18: 405-7.
7. Liu C, Zhang J, Wei X, et al. Effects of sleep duration and changes in body mass index on diabetic kidney disease: a prospective cohort study. *Front Endocrinol (Lausanne)* 2023; 14: 1278665.
8. Zamarron E, Jaureguizar A, Garcia-Sanchez A, et al. Continuous positive airway pressure effect on albuminuria progression in patients with obstructive sleep apnea and diabetic kidney disease: a randomized clinical trial. *Am J Respir Crit Care Med* 2023; 207: 757-67.
9. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *Am J Clin Nutr* 2016; 103: 965-78.
10. Jones SE, Lane JM, Wood AR, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. *Nat Commun* 2019; 10: 343.
11. Wang H, Lane JM, Jones SE, et al. Genome-wide association analysis of self-reported daytime sleepiness identifies 42 loci that suggest biological subtypes. *Nat Commun* 2019; 10: 3503.
12. Campos AI, Ingold N, Huang Y, et al. Discovery of genomic loci associated with sleep apnea risk through multi-trait GWAS analysis with snoring. *Sleep* 2023; 46: zzac308.
13. Jansen PR, Watanabe K, Stringer S, et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. *Nat Genet* 2019; 51: 394-403.

14. Wang J, Sun Z, Zhong Y, et al. Sleep disturbances and heart failure: observational study and mendelian randomization study. *Arch Med Sci* 2024; 21: 1222-32.
15. Wang Y, Liu S, Wu C, Yu H, Ji X. Association between circulating unsaturated fatty acid and preeclampsia: a two-sample Mendelian randomization study. *J Matern Fetal Neonatal Med* 2024; 37: 2294691.
16. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013; 37: 658-65.
17. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015; 44: 512-25.
18. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* 2016; 40: 304-14.
19. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* 2017; 46: 1985-98.
20. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med* 2017; 36: 1783-802.
21. Chaput JP, Dutil C, Featherstone R, et al. Sleep duration and health in adults: an overview of systematic reviews. *Appl Physiol Nutr Metab* 2020; 45: S218-31.
22. Wang D, Li W, Cui X, et al. Sleep duration and risk of coronary heart disease: a systematic review and meta-analysis of prospective cohort studies. *Int J Cardiol* 2016; 219: 231-9.
23. Shan Z, Ma H, Xie M, et al. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. *Diabetes Care* 2015; 38: 529-37.
24. Alterki A, Abu-Farha M, Al Shawaf E, Al-Mulla F, Abubaker J. Investigating the relationship between obstructive sleep apnoea, inflammation and cardio-metabolic diseases. *Int J Mol Sci* 2023; 24: 6807.
25. Dzierzewski JM, Donovan EK, Kay DB, Sannes TS, Bradbrook KE. Sleep inconsistency and markers of inflammation. *Front Neurol* 2020; 11: 1042.
26. Matoba K, Takeda Y, Nagai Y, Kawanami D, Utsunomiya K, Nishimura R. Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease. *Int J Mol Sci* 2019; 20: 3393.
27. Buyukaydin B, Akkoyunlu ME, Kazancioglu R, et al. The effect of sleep apnea syndrome on the development of diabetic nephropathy in patients with type 2 diabetes. *Diabetes Res Clin Pract* 2012; 98: 140-3.
28. Farhud DD. Hypothetical strategies of gene and environmental influence on life expectancy: a brief review. *Iran J Public Health* 2022; 51: 2382-7.
29. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. *Am J Epidemiol* 2013; 178: 1177-84.